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Phosphoinositide metabolism elicited by anti-CD9 monoclonal antibody, a well-characterized platelet activator, was studied using acetylsalicylic 
acid-treated human platelets. TP82, which is an anti-CD9 monoclonal antibody, induced classical phosphatidylinositol4,5-bisphosphate hydrolysis, 
as monitored by intracellular Ca*’ mobilization and phosphatidic acid production, and synthesis of phosphatidylinositol 3,4-bisphosphate, which 
is a major component of newly-described 3-phosphorylated inositol phospholipids produced during platelet activation. These changes were severely 
inhibited by 1 ,uM staurosporine, a potent, though non-selective, protein kinase inhibitor, which also abolished TP82 induction of tyrosine 
phosphorylation of multiple platelet proteins. Protein-tyrosine phosphorylation appears necessary to initiate both the classical phosphoinositide 
turnover and synthesis of the newly-described 3-phosphorylated inositol phospholipids in anti-CD9 monoclonal antibody-induced platelet 
activation. 
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1. INTRODUCTION 
CD9 antigen, one of the leukocyte differentiation an- 
tigens, is a 24-kDa surface-membrane glycoprotein 
present on platelets and a variety of hematopoietic and 
non-hematopoietic tissues [l]. Recent molecular cloning 
studies have revealed that it belongs to a new family of 
membrane-spanning proteins and has extensive similar- 
ity with a human melanoma-associated antigen ME491, 
a Schistosoma mansoni membrane protein SM23, and so 
on [2,3]. Although its physiological role remains to be 
elucidated, it is well established that anti-CD9 monoclo- 
nal antibody triggers platelet activation [4-141 mediated 
by the immunoglobulin G Fc receptor type II (FcyRII) 
[12-141. Anti-CD9 antibody-induced platelet activation 
involves phospholipase A, (PLA,) [9-l l] and phospho- 
lipase C (PLC) activation [5-81. However, the mecha- 
nism(s) by which the antibody acts on these effecters is 
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largely unknown. It is established that agonists such as 
thrombin, the receptor for which is a member of the 
seven transmembrane domain receptor family [ 151, in- 
duce guanine nucleotide-binding protein (G protein)- 
mediated PLC activation resulting in phosphatidylinos- 
itol 4,5-bisphosphate (PtdIns(4,5)P,) breakdown 
[16,17]. However, this might not be true for anti-CD9 
monoclonal antibody-induced PLC activation since 
CD9 antigen, with four putative transmembrane do- 
mains, belongs to a new family of cell-surface proteins 
which are completely different from G protein-coupled 
receptors [2,3]. 
Recently, a novel pathway of inositol phospholipid 
metabolism involving phosphatidylinositol (PtdIns) 3- 
kinase activation and resulting in the formation of 3- 
phosphorylated phosphoinositides has been discovered 
[17-201. Although generation of the newly described 
3-phosphorylated inositol lipids was originally shown to 
be associated with mitogenic responses and oncogenic 
transformation [18-201, terminally differentiated cells 
such as platelets have also been reported to generate the 
lipids upon stimulation with agonists such as thrombin 
[21-231. Furthermore, the agonistic stimulation of 
platelets resulted in enhanced protein-tyrosine phos- 
phorylation [24,25], which is likely to regulate PtdIns 
3-kinase activity [ 18-201. Hence platelet activation in- 
duced by anti-CD9 monoclonal antibody, as well as 
receptor-mediated agonists, may result in synthesis of 
3-phosphorylated phosphoinositides, because the anti- 
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body reportedly elicits protein-tyrosine phosphoryla- 
tion in human platelets [131. 
excitation signal in the absence of calcium, and F, is the same signal 
with the saturating calcium concentration. 
In the context described above, we show here that 
TP82, which is an anti-CD9 monoclonal antibody 
[4,26], induces classical PtdIns turnover, phosphatidyli- 
nositol 3,4-bisphosphate (PtdIns(3,4)P,) synthesis, and 
protein-tyrosine phosphorylation. All these changes 
were inhibited by staurosporine [27,28], a potent, al- 
though non-selective, protein kinase inhibitor, which 
may provide a clue with which to elucidate the mecha- 
nism of inositol phospholipid metabolism elicited by 
anti-CD9 monoclonal antibody. 
2.5. Platelet labeling with “P, and extraction of lipids 
2. MATERIALS AND METHODS 
Platelets at a cell density of 3 x lO?ml were resuspended in the 
buffer without NaH,PO,, then [“P]orthophosphate (0.5 mCi/ml) was 
added, and the platelets were incubated for 120 min at 37’C. The cells 
were then diluted and washed twice with the buffer (with added phos- 
phate). The 32P-labeled washed platelets (1 ml aliquots) were stimu- 
lated as indicated and the reactions were stopped by the addition of 
3 ml of CHC131CH30HIHCl (20:40:1, v/v) followed by thorough mix- 
ing and cooling at 4°C. One milliliter each of CHCl, and 100 mM 
EDTA was added into the mixture. After separation of aqueous and 
organic phases by centrifugation, the CHCI, layer was removed and 
another 2 ml of CHC13 was added to the samples and mixed well. The 
CHCI, layer was again removed and mixed with the previous CHCI, 
extract. Each sample was dried by evaporation under NZ. 
2.1. Materials 2.6. Deacylation of lipids 
The following materials were obtained from the indicated suppliers: 
[32P]orthophosphate (8,50&9,120 Ci/mmol), [?Z]phosphatidic acid 
(PA) (100-200 mCi/mmol), [1-3H]inositol 1,4,5_trisphosphate (15-30 
Ci/mmol), [I-‘Hlinositol 1,3,4+isphosphate (200-250 Ci/mmol), and 
Ptd[2-‘H]Ins(4,5)P, (2-10 Ci/tnmol) (DuPont-New England Nuclear, 
MA, USA); prostaglandin E, (Funakoshi, Tokyo, Japan); acetylsali- 
cylic acid (ASA) and bovine serum albumin (Sigma, MO, USA); 
thrombin (Green Cross, Osaka, Japan); staurosporine (Kyowa 
Medex, Tokyo, Japan); genistein (Extrasynthese, Genay, France); her- 
bimycin A and lavendustin A (Life Technologies, Inc., MD, USA); the 
anti-phosphotyrosine antibody PY20 (ICN, CA, USA); mouse IgG 
standard (Bethyl Laboratories, Inc., TX, USA); anti-v-src antibody 
(Ab-1) (Oncogene Science, Inc., NY, USA); the anti-FcyRII antibody 
IV.3 (Medarex, Inc., NH, USA); fura2-AM (Dojindo Laboratories, 
Kumamoto, Japan): TSK-Gel SAX HPLC column (TOSOH, Tokyo, 
Japan); methylamine (Aldrich, WI, USA). ST638 was kindly provided 
by Dr. T. Shiraishi (Biochemical Research Laboratories, Kanegafuchi 
Chemical Industry, Hyogo, Japan). TP82 was produced and purified 
as previously described [4]. 
Methylamine reagent (3 ml), consisting of methylamine/methanol/ 
H,Oln-butyl alcohol (prepared according to the method described by 
Clarke and Dawson [32]), was added to the dried lipids and incubated 
at 55°C for 60 min in a tightly stoppered tube. After the incubation, 
the mixture was cooled on ice, cold I-propanol (1.5 ml) added, and 
methylamine was removed in vacua. The samples were dried under N2, 
and the residue was dissolved in 1 ml of HZ0 and extracted with 1 ml 
of n-butyl alcohol/petroleum ether/ethyl formate (20:4:1, v/v). The 
upper phase containing fatty acids was discarded. The lower aqueous 
phase, containing water-soluble deacylated lipids, was washed twice 
with 1.0 ml of the above solvent mixture, and filtered. Glycero- 
phosphoinositides in the filtrate were separated on high performance 
liquid chromatography (HPLC). 
2.7. HPLC ofglycerophosphoinositides and inositol phosphates 
2.2. Platelet preparation 
Platelet-rich plasma was prepared as described previously [29]. The 
platelets obtained were washed and resuspended inthe buffer contain- 
ing 138 mM NaCl, 3.3 mM NaH,PO.,, 2.9 mM KCI, 1.0 mM MgCl,, 
1 mg/ml of glucose, and 20 mM HEPES (pH 7.4). The NaH*PO, was 
omitted when indicated. During all experiments, just before centrifu- 
gation of platelet suspensions, 15% vol. of acid-citrate-dextrose A 
solution (Terumo, Tokyo, Japan) or 1 PM prostaglandin E, was added 
to inhibit platelet activation. The choice of inhibitor did not affect the 
results. The final platelet count was adjusted to 3 x lO’/ml if not 
otherwise stated. The suspension was further supplemented with 1 
mM CaCI, 5 min before stimulation of the platelets. All experiments 
using intact platelet suspensions were performed at 37°C. 
Glycerophosphoinositides and inositol phosphates were separated 
by strong anion exchange (SAX) HPLC as described previously [29]. 
Authentic 14C-labeled PA and 3H-labeIed PtdIns(4,5)P, were used to 
confirm the positive identification of the lipids formed in platelets. We 
also verified the identification of PA, glycerophosphoinositol 3,4-bis- 
phosphate (GroPIns(3,4)P,), and glycerophosphoinositol 4,5-bis- 
phosphate (GroPIns(4,5)P,) by deglyceration of these lipids with 
NaIO, and dimethylhydrazine as described by Brown and Stewart [33] 
and that of the resulting Pi, inositol 1,3,4_trisphosphate, and inositol 
1,4,5_trisphosphate, r spectively. 
2.8. IdentiJication of phosphotyrosine-containing platelet proteins by 
immunoblotting 
2.3. Treatment with ASA 
The platelet suspension was incubated with 1 mM ASA, a cycloox- 
ygenase inhibitor, for 15 min to exclude the secondary effects of 
thromboxane A,. Under these conditions, production of thromboxane 
AZ was completely suppressed in cells stimulated with any agonists, 
which was confirmed by measuring thromboxane B, formation using 
a commercial radioimmunoassay kit (DuPont-NEN, MA, USA). 
2.4. (CaZ+/i measurement 
Protein-tyrosine phosphorylation was analyzed in platelet suspen- 
sions at a cell density of 9 x lO?ml. After platelet activation, the 
reactions were terminated with Laemmli SDS reducing buffer [34] plus 
500 mM Na,VO,, 10 mM EDTA, and 1 mM phenylmethanesulfonyl 
fluoride, followed by boiling for 3 min. Platelet proteins were sepa- 
rated by 8% SDS-PAGE [34], and electrophoretically transferred to 
Clear Blot Membrane-P (Atto, Tokyo, Japan). The membranes were 
blocked with 1% bovine serum albumin in phosphate-buffered saline. 
After extensive washing with phosphate-buffered saline containing 
0.1% Tween 80, the immunoblots were incubated for 3 h with 1 ,@ml 
of the monoclonal antibody PY-20, which specifically recognizes 
phosphotyrosine residues 1351, or control mouse IgG or 0.5 &ml of 
anti-v-src antibody. Antibody binding was detected using peroxidase 
conjugated goat anti-mouse IgG (Cappel, PA, USA) and visualized 
with ECL detection reagents (Amersham, UK). 
Platelet [Ca”], measurements were observed using fura as de- 
scribed previously [30]. [Caz’li values were calculated from fura ratios 
(R: the ratio of the fluorescence intensity at 340 nm to that at 380 nm) 
according to the equation [3 I]: [Ca”], = K,,(F,IF,)(R - R&l 
(R,,, - R), where Rmi. and R,, are the R-values obtained without 
Ca” and with the saturating concentration of calcium, respectively. 
Kd is the effective dissociation constant (224 nm), F, is the 380 nm 
3. RESULTS 
Although anti-CD9 monoclonal antibody-induced 
platelet stimulation involves activation of both PLC and 
PLA,, the secondary effects of thromboxane A, initi- 
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Fig. 1. [Ca*‘], increase and PA production induced by TP82 or throm- 
bin in ASA-treated human platelets. In A, time courses of [Ca*‘], 
transient (upper panel) and PA production (lower panel) induced by 
5 ,&ml TP82 or 0.1 U/ml thrombin are shown. In B, the effects of 5 
min pretreatment with 1 PM staurosporine on [Cal’], increase (upper 
panel) and PA production (lower panel) 5 min after the addition of 
5 ,&g/ml TP82 (white columns) or 0.1 U/ml thrombin (black columns) 
are shown. Each column represents the percent of the control value 
in the absence of the inhibitor and is the mean f S.E.M. from 3 
determinations. 
ated by PLA, activation are crucial in platelet activation 
induced by lower concentrations of the antibody [9-l 11. 
We previously reported that platelet activation, in terms 
of aggregation, release of intracellular granule contents, 
production of arachidonic acid metabolites, and eleva- 
tion of the intracellular Ca2’ concentration, induced by 
lower concentrations of TP82, a monoclonal antibody 
against CD9 antigen [4], is severely suppressed by ASA 
treatment [lo]. In this study, we used ASA-treated plate- 
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lets to eliminate the secondary effect of thromboxane A, 
(see section 2). We first observed Ca2’ mobilization and 
PA production, both reflecting PLC-catalyzed 
PtdIns(4,5)P, hydrolysis, induced by TP82. Although 
PA production can be attributed to hydrolysis of 
phosphatidylcholine by phospholipase D as well as hy- 
drolysis of PtdIns(4,5)P, by a PLC followed by phos- 
phorylation of the diacylglycerol produced, the former 
reportedly does not represent an important portion in 
human platelets [36]. Under the conditions employed, 
TP82, at a concentration as high as 5 puglml, induced 
PtdIns(4,5)P, hydrolysis; the time courses of Ca” mobi- 
lization and PA formation under TP82 (5 &ml) stimu- 
lation, along with those stimulated by thrombin (0.1 
U/ml), are shown in Fig. 1A. PtdIns turnover during the 
antibody-induced activation was delayed, with no ap- 
parent peak, but sustained Ca2’ mobilization and PA 
production were observed between 0 and 5 min when 
compared with those by thrombin, reaching a maxi- 
mum after O-l min (Fig. 1A). Pretreatment with 100 
,@ml of IV.3, an anti-FcyRII monoclonal antibody, 
abolished the TP82-induced PtdIns turnover (data not 
shown), which is consistent with the previous reports 
that anti-CD9 monoclonal antibody-triggered platelet 
activation is mediated by FcyRII [12-141. The 
PtdIns(4,5)P, hydrolysis induced by TP82 but not 
thrombin was inhibited by 1 ,uM staurosporine (Fig. 
lB), a potent, although non-selective, protein kinase 
inhibitor [27,28]. 
We next studied TP8Zinduced synthesis of 3- 
phosphorylated inositol phospholipids produced during 
platelet activation. The phospholipids extracted from 
32Pi-labeled human platelets were analyzed by SAX 
HPLC of their glycero-derivatives following deacyla- 
tion using methylamine. The elution pattern was similar 
to those previously reported [21,23,29]. Fig. 2A shows 
o- 
0 1 3 5 
Time (mm) 
Fig. 2. TP82-induced PtdIns(3,4)P, synthesis and its inhibition by staurosporine. GroPIns phosphates extracted and deacylated from platelets 
labeled with 32P, were separated by SAX HPLC as described in section 2. In A, HPLC analysis of deacylated ‘*P,-labeled lipids from the platelets 
without (left) or with (right) 5 min treatment with 5 pg/rnl TP82 is shown. The peaks of GroPIns(3,4)P, and GroPIns(4,5)P, are indicated. In B, 
the time course of TP82 (5 &ml)-induced PtdIns(3,4)P, production with (0) or without (0) 5 min pretreatment with 1 PM staurosporine are shown. 
Each point represents the percent of the maximum and is the mean of 2 or 3 experiments. 
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Fig. 3. TP82-induced protein-tyrosine phosphorylation and its inhibition by IV.3. In A, platelets were stimulated wttn 3 pgrni I IW for 0,1,3 and 
5 min, as indicated above lanes. The cells were then immunoblotted with PY20, which specifically recognizes phosphotyrosine residues, (left) or 
control mouse IgG (right) as described in section 2. The prominent tyrosine-phosphorylated protein bands, upon stimulation, are (in kDa): 64, 
75 and 97, and are indicated in the electrophoretogram. Although tyrosine phosphorylation of 125-kDa protein does occur weakly, it is difficult 
to clearly detect that because of a neighboring non-specific protein band. Other protein bands are also recognized by control mouse IgG as well 
as by PY20 and are hence considered to be non-specific. The location of pp60’“” was confirmed by immunoblotting with anti-v-src antibody. In 
B, platelets preincubated without or with 100 ,ug/ml IV.3 for 5 min were challenged without or with 5 &ml TP82 for 5 mitt, as indicated above 
lanes. The cells were then immunoblotted with PY20 (left) or control IgG (right) to identify phosphotyrosine-containing proteins. 
a typical HPLC profile of deacylated phospholipids ex- 
tracted from the platelets before and after stimulation 
of intact cells with 5 pg/ml of TP82; PtdIns(3,4)P, was 
absent from resting platelets, but was produced in the 
antibody-activated platelets. The TP82-induced synthe- 
sis of PtdIns(3,4)P, was time-dependent (Fig. 2B). As we 
had reported previously using thrombin-stimulated 
platelets [29], PtdIns(3,4)P, was the only species of 3- 
phosphorylated phosphoinositide which was generated 
upon platelet stimulation with TP82. The stimulated 
synthesis of PtdIns(3,4)P, was completely inhibited by 
100 pg/ml of IV.3 (data not shown) or staurosporine (1 
PM) (Fig. 2B). Under the conditions employed, we con- 
firmed our previous findings that thrombin (1 U/ml) 
induces PtdIns(3,4)P, synthesis and that it is completely 
abolished by 1 ,uM staurosporine [29]. 
Finally, platelets were incubated with TP82, and pro- 
tein-tyrosine phosphorylation was assessed by im- 
munoblotting. As shown in Fig. 3A, stimulation of 
platelets by treatment with 5 &ml of TP82 caused an 
induction of tyrosine phosphorylation of several plate- 
let proteins. The profile of tyrosine phosphorylation 
induced by TP82 was similar to that induced by throm- 
bin (see Fig. 4B) although in the former, the phospho- 
rylation was delayed and that of 125-kDa protein was 
not so apparent compared with the latter. The preincu- 
bation with 100 ,ug/ml of IV.3, an anti-FcyRII mono- 
clonal antibody, inhibited the anti-CD9 monoclonal an- 
tibody-induced tyrosine phosphorylation (Fig. 3B) as 
previously reported [ 131. However, we could not detect 
phosphorylation of the 40-kDa FcyRII itself, which had 
reportedly been observed in anti-CD9 antibody- but not 
in thrombin-stimulated platelets [13]. The reason for 
these discrepancies remains to be clarified. Again the 
tyrosine phosphorylation elicited by TP82 was com- 
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pletely suppressed by 1 PM staurosporine (Fig. 4A). 
Under the same conditions, protein-tyrosine phospho- 
rylation induced by thrombin was also inhibited by 
staurosporine pretreatment (Fig. 4B), as we reported 
previously [29]. 
4. DISCUSSION 
Although PLA, activation with resultant throm- 
boxane A, synthesis is crucial in platelet activation in- 
duced by anti-CD9 monoclonal antibody, especially at 
its lower concentrations [9-111, platelets can be fully 
activated even in the presence of ASA which inhibit 
cyclooxygenase and resultant thromboxane formation 
when challenged with high concentrations of TP82, 
which is an anti-CD9 [4]. The ASA-insensitive pathway 
is primarily mediated by PLC activation which hydro- 
lyzes PtdIns(4,5)P, and leads to a Ca2’ signaling path- 
way [5-81. We detected elayed PtdIns turnover induced 
by TP82 (Fig. 1A). The PLC activation induced by 
TP82 but not thrombin, the receptor for which is a 
member of the seven transmembrane domain receptor 
family, was blocked by staurosporine (Fig. 1B). This 
may provide a clue with which to elucidate the mecha- 
nism involving PLC activation induced by anti-CD9 
monoclonal antibody, which at present is largely un- 
known. 
Two mechanisms have been identified for receptor- 
stimulated activation of PLC [17,37,38]. One of these 
involves the mechanism which is similar to that of re- 
ceptor-regulated adenylate cyclase or photon-activated 
cyclic GMP phosphodiesterase and involves G proteins. 
The other involves protein-tyrosine kinase-mediated 
phosphorylation of PLC-y such as that triggered by 
platelet-derived growth factor receptor. It has been re- 
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Fig. 4. Inhibition by staurosporine of TP82 (A)- or thrombin (B)- 
induced protein-tyrosine phosphorylation. Platelet suspensions pre- 
treated with 1 PM staurosporine for 5 min were stimulated with 5 
&ml TP82 (CD9) or 0.1 U/ml thrombin (thr) for 5 min, as indicated 
above lanes. The cells were then immunoblotted with PY20 to identify 
phosphotyrosine-containing platelet proteins. 
ported that staurosporine, which non-specifically inhib- 
its several kinases including tyrosine kinase [27,28], 
clearly discriminates the two mechanisms of PLC acti- 
vation, dependent upon or independent of a protein- 
tyrosine kinase. The response through protein-tyrosine 
phosphorylation is completely suppressed by stauro- 
sporine pretreatment [3941], whereas that triggered by 
agonists mediated by the G protein-coupled receptor is 
not inhibited at all [41,42]. In this context, it is most 
likely that tyrosine phosphorylation plays an important 
role in PLC activation induced by anti-CD9 monoclo- 
nal antibody; PLC activation induced by TP82 but not 
thrombin, which acts on a G protein-coupled receptor 
[15], was inhibited by staurosporine (Fig. lB), which 
also inhibited TP82-induced protein-tyrosine phospho- 
rylation (Fig. 4A). For further study, we also examined 
the effect of specific tyrosine-kinase inhibitors such as 
genistein [43,44], ST638 [45], herbimycin A [46], and 
lavendustin A [44,47]. However, these agents did not 
effectively inhibit protein-tyrosine phosphorylation in 
human platelets (data not shown). 
We also showed the TP82-induced stimulation re- 
sulted in PtdIns(3,4)P, synthesis (Fig. 2) which, to our 
knowledge, is the first report of stimulated synthesis by 
anti-CD9 of 3-phosphorylated phosphoinositides. The 
PtdIns(3,4)P, synthesis was also abolished by 1 PM 
staurosporine. Since generation of 3-phosphorylated 
inositol phospholipids is supposed to be regulated by 
events requiring tyrosine kinase activity [ 18-201, stauro- 
sporine inhibition of PtdIns(3,4)P, synthesis is most 
likely due to its inhibition of protein-tyrosine phospho- 
rylation; it did inhibit protein-tyrosine phosphorylation 
elicited by TP82 (Fig. 4A). It is worth noting that stau- 
rosporine suppresses PtdIns(3,4)P, synthesis elicited by 
both TP82 (this study) and thrombin [29] although it 
exerts discriminating effects on PtdIns(4,5)P, hydrolysis 
induced by these stimulators, as described above. 
In conclusion, during anti-CD9 monoclonal anti- 
body-induced platelet activation, both the classical 
PtdIns turnover and the newly described 3- 
phosphorylated phosphoinositide synthesis were ob- 
served and these were abolished by staurosporine, 
which was also shown to inhibit protein-tyrosine phos- 
phorylation. It is assumed that tyrosine phosphoryla- 
tion initiates both the phosphoinositide metabolic path- 
ways in anti-CD9-induced platelet activation. 
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